Why is Piramal Pharma falling/rising?

As of 18-Jul, Piramal Pharma Ltd's stock is currently priced at Rs 211.20, reflecting a decline of Rs 5.3 or 2.45%. Today's performance indicates that the stock has underperformed its sector by 1.97%, with an intraday low of Rs 209.35, which represents a decrease of 3.3%. Over the past week, the stock has shown a positive return of 5.13%, and over the last month, it has increased by 9.03%. However, year-to-date, the stock is down 20.54%, despite a strong one-year return of 40.94%. The company has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 286.94%, and high institutional holdings at 46.27% suggest confidence among knowledgeable investors. Nevertheless, the stock faces challenges due to a high Debt to EBITDA ratio of 3.21 times, indicating a low ability to service debt, and a low Return on Equity of 0.87%, which reflects weak profitability.
Broader Market Context: In comparison to the benchmark, the Sensex has shown a slight decline of 0.90% over the past week, while Piramal Pharma's stock has outperformed this benchmark. However, the stock's year-to-date performance is significantly worse than the Sensex's gain of 4.63%. The broader market context reveals that despite the stock's strong one-year performance, it has struggled in the short term, which may be contributing to the current price decline. The market has generated negative returns of -0.36% in the last year, yet Piramal Pharma's substantial returns highlight its volatility and the potential impact of its financial metrics on investor sentiment.